Skip links and keyboard navigation

Genetics Cancer


If any of the following are present or suspected, please refer the patient to the emergency department (via ambulance if necessary) or seek emergent medical advice if in a remote region.

  • No referrals to emergency relating to clinical genetics

Please note this is not an exhaustive list of all conditions for outpatient services and does not exclude consideration for referral unless specifically stipulated in the CPC out of scope section. 

The following are not routinely provided in a public Genetics Cancer service.

Cancer Genetics

  • Individuals with a personal history of colorectal cancer diagnosed at age ≥ 50 years with loss of MLH1 and PMS2 on mismatch repair immunohistochemistry AND presence of the BRAF V600E mutation in tumour AND have no other personal or family history suggestive of a familial predisposition to colorectal cancer or gastrointestinal polyps.  For further information please see Colorectal Cancer condition within Genetics CPC and MMR IHC document on the GHQ website.
  • Individuals with a personal history of colorectal cancer diagnosed at age ≥ 50 years with normal mismatch repair immunohistochemistry AND have no other personal or family history suggestive of a familial predisposition to colorectal cancer or gastrointestinal polyps.  For further information please see Colorectal Cancer condition within Genetics CPC and MMR IHC document on the GHQ website.
  • Individuals with a personal history of endometrial cancer diagnosed at age ≥ 50 years with loss of MLH1 and PMS2 on mismatch repair immunohistochemistry AND presence of MLH1 promoter methylation in tumour AND have no other personal or family history suggestive of a familial predisposition to endometrial cancer.  For further information please see Female gynaecological cancer or tumour condition within Genetics CPC and MMR IHC document on the GHQ website.
  • Individuals with a personal history of endometrial cancer diagnosed at age ≥ 50 years with normal mismatch repair immunohistochemistry AND have no other personal or family history suggestive of a familial predisposition to endometrial cancer.  For further information please see Female gynaecological cancer or tumour condition within Genetics CPC and MMR IHC document on the GHQ website.
  • Individuals with melanoma who do not fulfil eviQ guidelines for CDKN2A or BAP1 gene testing (link) (eviQ BAP1 genetic testing guidelines pending)
  • Individuals who are solely being referred due to a family history of melanoma
  • Individuals who are solely being referred due to a family history of pancreatic cancer who do NOT fulfil one of the following criteria:
    • Three or more relatives with pancreatic cancer, at least one of whom is a first degree relative. 
    • At least two first degree relatives with pancreatic cancer
  • Individuals with a family history of cancer who are solely being referred for further assessment and management of a suspected new cancer (e.g. elevated tumour markers, abnormal breast imaging).
  • Individuals at increased risk of cancer who are solely being referred for ongoing management of cancer risk such as surveillance or risk reducing surgery.
  • Individuals solely being referred due to a family history of cancer which is unlikely to be associated with a familial cancer predisposition syndrome or increased risk of cancer for unaffected family members.
  • Individuals who are not residents of Queensland.
  • Individuals solely referred for a family history of bowel cancer who do NOT fulfil one or more of the following criteria: 
  • Individuals solely referred for a family history of breast cancer who do NOT fulfil one or more of the following criteria: 
    • fulfils criteria for the Medicare rebate for breast MRI
    • fits in the high (substantially increased) lifetime risk category according to iPrevent